CXCL9 and pneumonia: We demonstrated that the therapeutic treatment with a cationic peptide derived from the chemokine CXCL9(74–103) reduced the recruitment of neutrophils in murine models of LPS-induced lung inflammation and K. pneumoniae-induced pneumonia.